Mirum Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

- Net product sales for LIVMARLI® (maralixibat) oral solution totaled $17.5 million in the second quarter of 2022 and $28.4 million year-to-date

- Conference call to provide business updates today, August 4 at 1:30 p.m. PT/4:30 p.m. ET

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the second quarter ended June 30, 2022 and provided a business update.

“It is inspiring to see LIVMARLI’s impact on the burden of disease in Alagille syndrome and we continue to see growing demand with $17.5 million in net product sales in the second quarter,” said Chris Peetz, president and chief executive officer of Mirum. “We expect a strong finish to 2022 with topline MARCH PFIC Phase 3 data and anticipated EMA approval in Alagille syndrome by the end of the year.”

Key Operational Highlights

• Acquired Satiogen Pharmaceuticals, previously a licensing partner and now a wholly-owned subsidiary, reducing Mirum’s royalty and milestone obligations.
• Presented key data at recent medical conferences, including:
  • A six-year natural history comparison showing a 70% improvement (p-value